[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06479811 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

120

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Tumors
Kidney Cancers
Small Cell Lung Cancers
Pheochromocytoma/Paragangliomas
Gastrointestinal Neuroendocrine Tumors
Somatostatin Receptor Positive

Interventions

DRUG: 68Ga-DOTATATE
DRUG: [203Pb]VMT-alpha-NET
DRUG: [212Pb]VMT-alpha-NET

Sponsor

National Cancer Institute (NCI)